CD40LG and lymphoma: In a cohort of four lymphoma subgroups, which included patients on active treatment or within 3 months after completion of treatment, patients that were 3 to 6 months post-anti-CD20 treatment, patients between 6 and 9 months post-anti-CD20 treatment, and patients that were more than 9 months after CD20–directed therapy, it was found that none of the patients demonstrated a significant IgM response to the vaccination (20).